We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
Cap. Flow
+$275M
Cap. Flow %
2.78%
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$123M
2
NPCE icon
Neuropace
NPCE
+$93.1M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$77.8M
4
JANX icon
Janux Therapeutics
JANX
+$77.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$94.6M
2
ABCL icon
AbCellera Biologics
ABCL
+$54.5M
3
ADVM
Adverum Biotechnologies
ADVM
+$54.2M
4
MOH icon
Molina Healthcare
MOH
+$38M
5
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Miscellaneous 4.15%
3 Technology 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$498M 5.04%
6,044,266
-142,041
-2% -$10.8M
BMY icon
2
Bristol-Myers Squibb
BMY
$136B
$302M 3.05%
4,515,400
– –
EWTX icon
3
Edgewise Therapeutics
EWTX
$4.64B
$297M 3.01%
13,944,680
– –
BSX icon
4
Boston Scientific
BSX
$67.9B
$296M 2.99%
6,920,600
– –
MRK icon
5
Merck
MRK
$366B
$290M 2.94%
3,732,400
-179,155
-5% -$13.3M
PRLD icon
6
Prelude Therapeutics
PRLD
$437M
$287M 2.91%
10,039,691
– –
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$274M 2.77%
2,922,155
-222,200
-7% -$20.4M
SPRY icon
8
ARS Pharmaceuticals
SPRY
$586M
$270M 2.73%
8,740,887
– –
PMVP icon
9
PMV Pharmaceuticals
PMVP
$65.2M
$250M 2.53%
7,330,423
– –
NTRA icon
10
Natera
NTRA
$47B
$234M 2.36%
2,057,800
-138,100
-6% -$14.1M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$137B
$215M 2.17%
1,065,400
-70,500
-6% -$14.7M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$204M 2.07%
1,264,200
+43,000
+4% +$6.9M
TPTX
13
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$184M 1.86%
2,361,327
– –
IOVA icon
14
Iovance Biotherapeutics
IOVA
$3.63B
$173M 1.75%
6,645,100
– –
ARQT icon
15
Arcutis Biotherapeutics
ARQT
$2.99B
$166M 1.68%
6,073,850
– –
UNH icon
16
UnitedHealth
UNH
$353B
$156M 1.58%
389,700
-13,300
-3% -$5.3M
GH icon
17
Guardant Health
GH
$21.7B
$152M 1.54%
1,227,400
+250,000
+26% +$33.6M
HUM icon
18
Humana
HUM
$46.3B
$148M 1.5%
335,000
+21,400
+7% +$9.35M
ABCL icon
19
AbCellera Biologics
ABCL
$3.68B
$137M 1.38%
6,223,019
-1,977,749
-24% -$54.5M
ABBV icon
20
AbbVie
ABBV
$451B
$132M 1.33%
1,167,500
-45,700
-4% -$5.15M
ISRG icon
21
Intuitive Surgical
ISRG
$132B
$128M 1.3%
418,800
– –
ELV icon
22
Elevance Health
ELV
$85.5B
$128M 1.3%
335,700
+49,100
+17% +$18.8M
DXCM icon
23
DexCom
DXCM
$34.3B
$127M 1.28%
1,189,600
– –
XBI icon
24
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$127M 1.28%
+935,700
New +$123M
DCPH
25
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$121M 1.22%
3,297,301
+1,916,401
+139% +$74.2M
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2021 Portfolio in Review

As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
  • OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
  • OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
  • OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
  • OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
  • OrbiMed opened 24 new positions and closed 24 in Q2 2021.
  • OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.